• Explore /
  • Poster
  • / A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.

A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.

Abstract Poster

Authors

null

Nizar M. Tannir

University of Texas MD Anderson Cancer Center, Houston, TX

Nizar M. Tannir , Neeraj Agarwal , Sumanta K. Pal , Maria Nirvana Formiga , Jun Guo , Daniel J. George , Mary Ann Tagliaferri , Alison L. Hannah , Jenny Yanzhen Zhang , Bridget A. O'Keeffe , Daniel C. Cho

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03729245

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS4595)

DOI

10.1200/JCO.2019.37.15_suppl.TPS4595

Abstract #

TPS4595

Poster Bd #

416b

Abstract Disclosures

Similar Posters

First Author: Nizar M. Tannir

First Author: Toni K. Choueiri

First Author: Nikhil I. Khushalani

First Author: Elena Verzoni